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ARTICLE
Collaborative interactions of heterogenous
ribonucleoproteins contribute to transcriptional
regulation of sterol metabolism in mice
Zhengyi Zhang1,2, An-Chieh Feng3,4,5, David Salisbury1,3, Xin Liu3, Xiaohui Wu1,2, Jason Kim1,2, Irina Lapina1,2,
Dan Wang1,2, Brennan Lee1,2, Josue Fraga1, Calvin Pan 1,6, Kevin J. Williams7, Aldons J. Lusis 1,6,
Phil Scumpia4 & Tamer Sallam1,2,8✉
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are a group of functionally versatile
proteins that play critical roles in the biogenesis, cellular localization and transport of RNA.
Here, we outline a role for hnRNPs in gene regulatory circuits controlling sterol homeostasis.
Specifically, we find that tissue-selective loss of the conserved hnRNP RALY enriches for
metabolic pathways. Liver-specific deletion of RALY alters hepatic lipid content and serum
cholesterol level. In vivo interrogation of chromatin architecture and genome-wide RALY-
binding pattern reveal insights into its cooperative interactions and mode of action in reg-
ulating cholesterogenesis. Interestingly, we find that RALY binds the promoter region of the
master metabolic regulator Srebp2 and show that it directly interacts with coactivator Nuclear
Transcription Factor Y (NFY) to influence cholesterogenic gene expression. Our work offers
insights into mechanisms orchestrating selective promoter activation in metabolic control
and a model by which hnRNPs can impact health and disease states.
https://doi.org/10.1038/s41467-020-14711-4 OPEN
1 Division of Cardiology, Department of Medicine, University of California, Los Angeles, CA 90095, USA. 2Molecular Biology Institute, University of California,
Los Angeles, CA 90095, USA. 3Molecular Biology Interdepartmental Doctoral Program, University of California, Los Angeles, CA 90095, USA. 4Division of
Dermatology, Department of Medicine, University of California, Los Angeles, CA 90095, USA. 5Department of Microbiology, Immunology and Molecular
Genetics, University of California, Los Angeles 90095, USA. 6Department of Human Genetics, University of California, Los Angeles, CA 90095, USA.
7Department of Biological Chemistry, University of California, Los Angeles, CA 90095, USA. 8Molecular, Cellular and Integrative Physiology Program,
University of California, Los Angeles, CA 90095, USA. ✉email: tsallam@mednet.ucla.edu
NATURE COMMUNICATIONS |          (2020) 11:984 | https://doi.org/10.1038/s41467-020-14711-4 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Heterogeneous nuclear ribonucleoproteins (hnRNPs) are afamily of multifunctional RNA-binding proteins withcritical roles in gene regulation. Cooperative activities of
hnRNPs have been shown to impact various aspects of RNA
metabolism1. Although much of the focus on hnRNPs has been
geared to their role in splicing and transcript processing, their
direct effects on mRNA biogenesis are far less understood with
limited compelling roles for transcriptional contributions of
hnRNPs. In addition, several lines of evidence link hnRNP
abnormalities to neurodegenerative diseases and cancer, but their
impact in metabolic control remains unexplored2,3.
A number of genome-wide association studies have linked
variants at the hnRNP RALY (also known as heterogeneous
nuclear ribonucleoprotein C-like 2) with cardiometabolic traits,
including total cholesterol and coronary artery disease, yet little is
known about the function and mechanisms of actions of RALY4–6.
Our previous studies have shown that RALY interacts with LeXis,
a noncoding RNA mediating crosstalk between the cholesterol
biosynthesis and efflux pathways7. LeXis is a direct transcriptional
target of LXR, a sterol-sensing nuclear receptor that triggers an
“emergency response” to a lipid overload state. Activation of LXR
induces the expression of genes involved in cholesterol efflux
(ABCA1 and ABCG1), limiting lipid uptake (IDOL), and pro-
moting triglyceride-rich lipoprotein formation (SREBP1C and
SCD1)8. On the other hand, the sterol regulatory element-binding
proteins (SREBPs) are master regulators of sterol metabolism,
directly activating the expression of genes involved in cholesterol
and fatty acid biosynthesis9. Although all SREBP isoforms can
influence a large repertoire of genes at extreme perturbations, it is
well established that SREBP1c preferentially activates genes
involved in fatty acid biosynthesis, whereas SREBP2 influences
cholesterol biosynthetic machinery10. Consistent with unique
epistatic relationship between various SREBPs, loss of SREBP2 in
mouse liver reduces SREBP1c and triglyceride levels in addition to
impacting cholesterol stores11. Despite their unique activation
signature both isoforms appear to bind similar DNA response
elements and to partner with common transcriptional coactiva-
tors, including Nuclear Transcription Factor Y (NFY) and SP1
(ref. 12,13).
In this work, we outline a role for hnRNPs in regulatory cir-
cuits controlling sterol homeostasis. Liver-specific deletion of the
hnRNP Raly lowers serum cholesterol and hepatic lipid content.
By mapping RALY-binding sites and utilizing unbiased chro-
matin interrogation techniques, we show preferential binding
patterns of RALY at gene promoter regions and decipher its
cooperative interactions. Intriguingly, we find that RALY binds at
the Srebp2 but not Srebp1 promoter region, and show that it
interacts directly with NFY to influence transcription of choles-
terogenic genes. Our work offers insights into mechanisms
orchestrating selective promoter activation and a model by which
hnRNPs can impact metabolic disease states.
Results
Ablation of Raly impacts cholesterol biosynthetic genes. To
gain insights into the contribution of hnRNPs in metabolic
disease, we generated mice with LoxP sites flanking exons 3 and
4 of Raly (Fig. 1a, Supplementary Fig. 1). Administration of a
Cre or control adenovirus to Ralyflox/flox primary murine
hepatocytes resulted in the ablation of RALY transcript and
protein levels (Supplementary Fig. 2a, b). Since RALY is one of
the few hnRNPs linked to human lipid traits, and since our
previous studies have shown that disruption of the LeXis-RALY
axis perturbs cholesterogenic gene expression, we sought to
determine the effect of genetic deletion of Raly on Srebp2
(official gene symbol Srebf2) gene expression. Deletion of Raly
from primary murine hepatocytes led to a significant reduction
of Srebp2 and its target genes involved in cholesterol bio-
synthesis, including Hmgcr (Supplementary Fig. 2c). Surpris-
ingly, the deletion of Raly from mouse hepatocytes also led to a
significant reduction in Srebp1c, the isoform responsible for
triglyceride biosynthesis (Supplementary Fig. 2c). We confirmed
reduced protein levels of a nuclear SREBP2 and a number of
targets, including 3-Hydroxy-3-Methylglutaryl-CoA Synthase
(HMGCS) and Farnesyl Diphosphate Synthase (FDPS) (Sup-
plementary Fig. 2d, e). To explore the contributions of Raly in
liver metabolism, we generated liver-specific Raly knockout
mice (referred to as L-RalyKO while Ralyflox/flox Cre-negative
littermates are controls). Quantitative PCR (qPCR) analysis and
western blotting confirmed significant and robust decrease in
RALY in liver following Cre recombination (Fig. 1b, c). Previous
studies have shown that at least a subset of hnRNP complexes
influence gene expression in a non-discriminate fashion14. To
better define the range of RALY activities in liver, we performed
unbiased transcriptional profiling of livers from L-RalyKO and
control mice on chow diet (Fig. 1d). Analysis of differentially
regulated genes showed a significant and strong enrichment of
lipid metabolic and related pathways (Fig. 1e), as well as sub-
stantial overlap with pathways known to be modulated by
SREBP2 (Fig. 1e)15. qPCR showed a significant reduction in
expression of Srebp2 and its target genes in L-RalyKO mice
(Fig. 1f). There was also a trend to reduced Srebp1c expression
although did not reach significance (fasting mice). Consistent
with gene expressing results loss of RALY was associated with a
reduction in serum cholesterol level (Fig. 1g). Lipid fractiona-
tion analysis revealed a reduction in low-density lipoprotein
(LDL) and high-density lipoprotein fractions the predominant
circulating pool in chow-few mice (Fig. 1h). Taken together,
these results suggest that hnRNPs can regulate the activity of
specific gene expression programs and that the effects of RALY
on cholesterogenesis are non-redundant.
Liver-specific deletion of Raly reduces hepatic sterol content.
We noted that loss of Raly from hepatocytes was associated with a
decrease in cellular cholesterol and triglyceride content (Fig. 2a,
b). To better define the contributions of RALY on hepatic lipid
composition, we performed unbiased shotgun lipidomics on
mouse liver comparing L-RalyKO and controls. We observed that
vast majority of lipid species were unchanged with the exception
of hepatic cholesterol and triglyceride content (Fig. 2, Supple-
mentary Fig. 3). Examination of cholesterol esters showed a
reduction in most species in L-RalyKO although only a subset
reached statistical significance (Fig. 2c, d). Similarly triglyceride
content was significantly reduced in L-RalyKO livers (Fig. 2e, f).
We observed no changes in the expression of genes involved in
lipolysis (Supplementary Fig. 4). Intriguingly, these results par-
tially phenocopy the chow-fed Srebp2 liver-specific knockout
mice, that exhibit mildly reduced liver cholesterol content as well
altered SREBP1c and triglycerides levels11. These results are also
consistent with unique epistatic relationship between various
SREBPs. Taken together, the lipidomics findings reinforce the
gene expression results and support the notion that RALY may be
affecting sterol metabolism through interaction with the Srebp2
pathway. To more thoroughly investigate the contributions of
RALY in chronic lipid abundance states, we fed L-RalyKO mice
and controls a diet known to induce sterol accumulation and
Non-Alcoholic Steatohepatitis (NASH). After 9 weeks of feeding,
L-RalyKO showed significant reduction in Oil Red O staining
(Fig. 2g, h). These results demonstrate that in a preclinical disease
model the hepatic loss of RALY partially protects against lipid
overload.
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DNA binding of RALY enriches for metabolic regulators. Our
previous studies have shown that LeXis and RALY are almost
exclusively present in the cell nucleus in association with chro-
matin and that LeXis may be impacting cholesterogenic gene
expression through transcriptional mechanisms7. Thus, we
hypothesized that RALY may also be impacting Srebp2 levels
through nascent transcript production. To gain better insight as
to how RALY may regulate gene expression, we mapped genome-
wide RALY-binding sites. We performed chromatin immuno-
precipitation sequencing (ChIP-seq) to assess RALY DNA bind-
ing in murine hepatocytes and identified a total of 2950 RALY
peaks that were independent identified by the same peak calling
algorithm in at least two independent samples (Fig. 3a). Global
analysis of fragment distribution around the peak summit showed
overall agreement between samples and a broad peak contour
profile spanning ~500 bps, a feature often associated with cor-
egulators (Fig. 3b). Interestingly, RALY showed strong enrich-
ment for promoter binding but was also in enriched in other parts
of the genome, including intronic and intergenic regions (Fig. 3c,
d). Furthermore, unbiased peaking calling showed that RALY
bound the Srebp2 promoter region but not the Srebp1 promoter
(Fig. 3d, Supplementary Fig. 5). These results reinforce the notion
that RALY primarily affects Srebp2 and that perturbations in
hepatic triglycerides content are likely a downstream consequence
of reduced SREBP2 activity. In addition, motif discovery analysis
of RALY-bound peaks identified the transcription factor NFY as a
highly enriched motif (Fig. 3e). NFY is a promoter-binding
transcription factor (formed with trimeric complex of NFYA,
NFYB, and NFYC with all subunits required for proper function)
with an established role in mediating SREBP responses16. Taken
together, these results hint that RALY may be influencing cho-
lesterogenesis by modulating collaborative interactions with
transcriptional coactivators at the Srebp2 promoter.
A number of studies have shown that noncoding RNA–protein
interactions can regulate gene activities by modulating a number
of histone modifications at target genes17,18. To explore the
possibility that RALY may influence gene expression by altering
epigenetic states, we performed Assay for Transposase-Accessible
Chromatin using sequencing (ATAC-seq)19, a method that allows
unbiased interrogation of chromatin architecture, on livers from
L-RalyKO and controls (Fig. 3f). Loss of RALY in mouse liver did
not globally alter chromatin accessibility (Fig. 3g) arguing against
the idea that RALY may be impacting gene expression by
impacting histone modifiers, such as polycomb repressive
15
1 2 3 4 Neo 5
Neo deletion
after FLP
Cre
recombination
Exon
25
Raly
Actin
35 KD
42 KD
20
15
10
N
or
m
a
liz
e
d 
ex
pr
es
sio
n
5
0
10
8
6
4
–
lo
g1
0 
(P
-
va
lu
e)
2
0
Ph
os
ph
op
ro
te
in
Ki
na
se
Tr
a
n
sc
rip
tio
n 
 re
gu
la
tio
n
Sr
/T
hr
-p
ro
te
in
 k
in
as
e
Tr
a
n
sf
e
ra
se
G
lyc
op
ro
te
in
D
N
A-
bi
nd
in
g
Si
gn
al
 tr
a
n
sd
uc
tio
n
D
ev
e
lo
pm
en
ta
l p
ro
te
in
Ub
l c
on
jug
ati
on
M
et
al
-b
in
di
ng
2.5
150 0.25
0.2
Ch
ol
es
te
ro
l (m
mo
l/L
)
0.15
0.1
0.05 VLDL
LDL
HDL
0
Time of fraction collection (minutes)
Ch
ol
es
te
ro
l (m
g/d
L)
100
50
0
2.0
R
el
at
ive
 g
en
e 
ex
pr
es
sio
n
1.5
1.0
0.0
Sre
bp
2
Sre
bp
1c
Hm
gcs Fd
ps
Fd
ft1
0.5
L-Cre– L-Cre+
L-Cre– L-Cre+
L-Cre– L-Cre+
L-Cre–
L-Cre+
L-Cre– L-Cre+
Homology arm cKO regionLoxP site Frt site
9
1 2 3 4 5 9
Targeted Allele
Raly
Conditional KO Allele
KO Allele
1 2 5 9
–
lo
g1
0 
(P
-
va
lu
e)
10
5
0
–6 –4 –2 0
Fold change
2 4 6
Tr
a
n
sc
rip
tio
n
Ap
op
to
sis
R
ep
re
ss
or
Cy
to
pl
as
m
H
ep
ar
in
-b
in
di
ng
N
uc
le
us
D
is
ul
fid
e 
bo
nd
D
iff
e
re
n
tia
tio
n
N
uc
le
ot
id
e-
bi
nd
in
g
En
do
pl
as
m
ic 
re
tic
ul
um Zi
nc
M
ag
ne
siu
m
Li
pi
d 
m
et
ab
ol
ism
M
on
oo
xy
ge
na
se
Ph
er
om
on
e-
bi
nd
in
g
Ac
tiv
a
to
r
G
TP
a
se
 a
ct
iva
tio
n
Li
po
pr
ot
ei
n
AT
P-
bi
nd
in
g
Se
cr
et
ed
Se
rin
e 
pr
ot
ea
se
 in
hi
bi
to
r
Al
te
rn
at
iv
e 
sp
lic
in
g
Cy
cli
n
H
em
e
Un
fo
ld
ed
 p
ro
te
in
 re
sp
on
se
N
eu
ro
ge
ne
sis
G
ol
gi
 a
pp
ar
a
tu
s
Pr
ot
ea
se
 in
hi
bi
to
r
Pa
lm
ita
te
An
gi
og
en
es
is
G
lu
co
ne
og
en
es
is
St
er
oi
d 
m
et
ab
ol
ism
In
fla
m
m
at
or
y 
re
sp
on
se
M
ic
ro
so
m
e
Li
pi
d 
dr
op
le
t
Zi
nc
-fi
ng
er
Si
gn
al
An
tip
or
t
Ch
ol
es
te
ro
l m
et
ab
ol
ism
G
PI
-a
nc
ho
r
Iro
n
St
er
ol
 m
et
ab
ol
ism
a b c
d e
f g h
Fig. 1 Loss of RALY reduces Srebp2 and specifically enriches for metabolic pathways. a Schematic of Raly conditional knockout strategy. b Gene
expression of RALY in liver from chow-fed mice (n= 8 per group). c Protein level of RALY in liver from chow-fed mice (n= 8 per group). d Volcano plot of
RNA-seq results from liver with and without RALY (n= 4 per group). e Enriched functional terms from RNA-seq of differentially regulated genes from
mouse liver. Yellow bar indicates functional keyword is also enriched in liver SREBP2 ChIP. f Gene expression in mice liver on chow diet (n= 8 per group).
g Total serum cholesterol levels isolated from chow-fed mice (n= 8 per group). h Cholesterol levels in pooled fractionated serum from mice in g. All data
are mean ± SD. *P < 0.05; **P < 0.01, and ***P < 0.001, using two-tailed Student’s t-test.
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Fig. 2 Liver-specific deletion of RALY alters hepatic lipid content. a, b Cholesterol level a and triglycerides level b from primary hepatocytes relative to
baseline levels (normalized to cell number). c, d Lipidomics investigation of cholesterol ester (CE) species from liver from L-Raly knockout mice and
controls (n= 4 per group). e, f Lipidomics investigation of triglycerides species from liver from L-Raly knockout mice and controls (n= 4 per group). Each
line on heat map represents an individual triglyceride species of 411 different triglycerides detected (four mice per group). g Oil Red O (ORO) staining of
liver from NASH diet-fed mice (scale bar, 20 µm). h Quantification of positive ORO staining area from done with automated image j detection. Values are
shown as means ± SD. *P < 0.05 and **P < 0.01, using two-tailed Student’s t-test.
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complex proteins or histone deacetylase20. In addition to directly
interrogating changes in nucleosome rearrangements, ATAC-seq
allowed us to infer transcriptional activity by examining changes
in enhancer landscapes with targeted perturbations. Although
globally most ATAC peaks did not change between controls and
L-RalyKO samples, a number of peaks were differentially
regulated (Fig. 3h). Intriguingly, many of these peaks clustered
near genes involved in lipid metabolism (Fig. 3i, j, Supplementary
Fig. 6). Furthermore, motif analysis of these differentially altered
peaks showed specific enrichment for number of transcription
factors known to impact metabolic regulation, including NFY
(Fig. 3k). Taken together, the above results suggest that RALY
may be regulating cholesterol metabolism by impacting the
coactivator NFY at the Srebp2 gene.
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RALY is required for NFY-dependent activation of Srebp2. To
clarify whether RALY directly interacts with transcriptional
machinery at SREBP2, we performed co-immunoprecipitation
(Co-IP) studies in murine hepatocytes. Pulldown of RALY enri-
ches for NFY and vice versa confirming a robust interaction
between the two factors (Fig. 4a, b). To clarify whether RALY is
required for NFY binding at promoter regions, we performed
ChIP of NFY in L-RalyKO or control livers. We confirmed NFY
enrichment at its known target gene Rnf5 (Fig. 4c), as well as the
SREBP2 promoter region (Fig. 4d). Our results suggest that NFY
binding is minimally rearranged by the loss of RALY consistent
with the idea that RALY does not act as a guide to facilitate NFY
complex DNA binding, rather it works cooperatively with NFY at
select sites to influence its transcriptional activity. To determine if
RALY was sufficient to induce the expression of cholesterogenic
genes, we overexpressed RALY using an adenoviral vector in a
murine hepatocyte cell line (Supplementary Fig. 7). We found
that cholesterogenic gene expression was increased in response to
RALY expression (Fig. 4e). In addition, hepatic RALY over-
expression increased serum cholesterol in chow-fed mice (Fig. 4f).
To more thoroughly investigate the cooperative relationship
between RALY and cis/trans promoter factors, we performed
luciferase reporter assays with an Srebp2 promoter construct
(Fig. 4g). Adenoviral expression of RALY in hepatocytes
enhanced wild-type Srebp2 promoter-driven luciferase activity,
but failed to increase luciferase activity when either NFY or SRE
sites were mutated (Fig. 4d). These results reinforce the idea that
RALY is a coactivator that requires the binding of canonical
transcriptional factors at the Srebp2 promoter including SREBP
itself. To better clarify the epistatic relationship between NFY and
RALY, we performed a knockdown of NFY in RALY-deficient
cells. Our results show that reduction of NFY on a Raly-deficient
background no longer alters Srebp2 expression (Fig. 4h, Supple-
mentary Fig. 8). These results suggest that RALY is required for
NFY-dependent transcription of SREBP2 and is consistent with
notion, and RALY and NFY work cooperatively to influence gene
expression.
To better explore the relationship between hnRNPs and human
lipid traits, we analyzed expression data from the METISM
cohort21. Interestingly, expression of RALY was positively asso-
ciated with a number of metabolic, traits including total and LDL
serum cholesterol levels though the strength of association was
modest (Fig. 4i). Importantly, other hnRNPs, including ones that
contribute to transcriptional control mechanisms (hnRNP K), were
not significantly associated with total cholesterol or LDL cholesterol
in this cohort (Supplementary Fig. 9). Although hnRNPs are known
to form complexes with one another, these observations are
consistent with the idea that individual hnRNPs may play
functional roles favoring specific pathways
Discussion
Previous work has identified important roles for hnRNPs in
neurodegenerative disease, most prominently amyotrophic lateral
sclerosis and frontotemporal lobar degeneration1,2. Our work
expands the contributions of hnRNPs in health and disease by
showing that a conserved hnRNP can help direct the fundamental
metabolic regulatory circuits. In addition, our work offers insights
into the precise molecular mechanisms that link hnRNP
abnormalities with pathologic states. The functional versatility of
hnRNPs is thought to stem from their ability to “dance with
different partners” to impact diverse biologic process, such as
RNA splicing, polyadenylation, export, and translation. Thus,
there are potentially multiple ways by which hnRNPs abnorm-
alities can lead to disease states. Defects in hnRNPs leading to
stress granule changes and the accumulation of pathological
inclusions are thought to be important in neurodegenerative
states22,23. Our work shows that hnRNPs proactively participate
in transcriptional control mechanisms regulating cholesterol
homeostasis and that loss of a single hnRNP (RALY) influences
hepatic lipid stores. It should be noted that our work does not
exclude the possibility that RALY may play other functional roles
or influence gene regulation though multiple mechanisms. In
addition, RALY may be impacting transcript splicing or other
redundant functions that may be masked in our knockout model
or perhaps more critical in other tissues or cell types. Intriguingly,
we find that RALY has multiple isoforms and it is unclear whe-
ther different isoforms perform different functions.
It is well established that the predominantly cholesterogenic
SREBP2 and lipogenic SREBP1 transcription factors may be
differentially processed depending on the environment cues.
However, both isoforms are capable of binding diverse SREs and
collaborate with common coactivators despite possessing distinct
transcriptional effects once in the nucleus. In addition, it is
unclear how generic collaborative partners, such as NFY and SP1
are capable of turning on some but not all their target genes in
response to specific environmental cues. The characterization of
RALY offers some important clues into the selective promoter
activities of different SREBPs. The fact that RALY binds the
promoter of one isoform (Srebp2) and not the other hints that
spatial collaborative interactions may favor a specific gene acti-
vation signature. The finding that RALY interacts with the SREBP
coactivator NFY also raises a number of intriguing questions.
How do hnRNPs influence some genes but not others? and what
is the biochemical basis for their interactions? can RALY directly
collaborate with other transcriptional regulators besides NFY?
Future studies will provide more insights into these questions.
Methods
Study approval. All experiments were approved by the UCLA Institutional Ani-
mal Care and Research Advisory Committee and performed in strict accordance
with the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. Please see supplemental materials for
detailed methods.
Animals. All animals used in the study were in C57BL/6 background. Our study
used male mice unless otherwise specified. Mice were fed chow diet (Research Diet)
and housed temperature-controlled room under a 12-h light/12-h dark cycle and
pathogen-free conditions. Ralyflox/flox mice were generated by Cyagen using the
strategy outlined in Fig. 1a. To the generated RALY liver-specific knockout mice
and littermate controls, we treated Ralyflox/flox with adeno-associated virus (AAV)
with TBG promoter (AAV8.TBG.Cre) or (AAV8.TBG.GFP; green fluorescent
protein) purchased from Penn Vector Core. AAV administered intraperitoneal
injection at dose of 5 × 1011 GC per mice. Mice were euthanized 4 weeks after AAV
injection. Liver tissues were frozen in liquid nitrogen and stored at −80 °C or fixed
in 10% formalin. Blood was collected by retro-orbital bleeding, and the plasma was
separated by centrifugation. Plasma lipids were measured with the Wako L-Type
TG M kit, the Wako Cholesterol E kit. All animal experiments were approved by
the UCLA Institutional Animal Care and Research Advisory Committee.
Cells culture. Mouse primary hepatocytes were isolated as previously described
and cultured in William’s E medium with 5% bovine serum albumin (BSA)24.
Hepa1-6 cells were originally obtained from ATCC and cultured in Dulbecco's
Modified Eagle Medium (DMEM) medium with 10% fetal bovine serum (FBS).
Adenovirus studies were performed as previously described7. RALY was cloned
from mouse cDNA using a gateway cloning system and into the pAd/CMV/V5-
DEST Gateway vector by LR recombination according to the manufactures
guidelines. NFY knockdown was done in primary hepatocytes using short inter-
fering RNA against nfya (DharmaconTM catalog number LQ-065522-00-0005).
Transfection was proceed using DharmaFECTTM 4 transfection reagent (Dhar-
maconTM) according to the manufacturers recommendation. Cells were collected
for RNA isolation or protein extraction 48 h after transfection.
Gene expression analysis and immunoblot analysis. Total RNA was isolated
using TRIzol reagent (Invitrogen) and reverse transcribed using a homemade RT, as
we previously described25. cDNA was quantified by real-time PCR using SYBR Green
Master Mix (Diagenode) on BioRad Real-time PCR instrument. Gene expression
levels were determined by using a standard curve. Each gene was normalized to the
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housekeeping gene 36B4. For immunoblot analysis, whole cell lysate or tissue lysate
was extracted using RIPA lysis buffer (Boston Bioproducts) supplemented with
complete protease inhibitor cocktail (Roche). For SREBP2 proteins immunoblot
analysis, nuclei from primary hepatocytes were prepared using Subcellular Protein
Fractionation Kit for Cultured Cells (78840, Thermo Scientific). Proteins were diluted
in Nupage loading dye (Invitrogen), heated at 95 °C for 5 min, and run on 4–12%
NuPAGE Bis-Tris Gel (Invitrogen). Proteins were transferred to hybond ECL
membrane (GE Healthcare) blocked with 5% milk (or 5% BSA for anti-SREBP2) to
quench nonspecific protein binding and blotted with the indicated primary antibody.
For complete listing of antibodies and primers please see Supplementary Table 1.
Uncropped blots are provided in Supplementary Fig. 10.
Dual luciferase assay. DNA transfection of Hepa1-6 cells was performed with
LipofectamineTM 3000 (Invitrogen) according to user’s manuscript on 24-well
plates with a cell density of 1.5 × 105 cells/well. The cells were transfected with
200 ng of the Srebp2 promoter firefly reporter plasmid, 50 ng of Renilla reporter
plasmid (Promega), and 200 ng of nSREBP2 expression vector. At 12 h after
transfection, the cells were cultured in DMEM supplemented with 1% (v/v) FBS
and adenovirus was administered. After 24 h, assays for both luciferase and Renilla
activities were performed. The reporter activities were expressed as the relative
firefly luciferase activity/Renilla luciferase activity.
RNA-seq. Libraries for RNA-Seq were prepared with KAPA Stranded RNA-Seq
Kit on RNA isolated from livers of chow diet feeding mice with AAV-GFP or
AAV-Cre transduction. The data were sequenced on Illumina HiSeq 3000 for a
pair-end 150 bp read run. Data quality check were done on Illumina SAV.
Demultiplexing was performed with Illumina Bcl2fastq2 v 2.17 program. RNA-seq
reads were aligned with TopHatv2.0.2 to the mouse genome, version mm9 25.
Transcripts were assessed and quantities were determined by Cufflinks v2.0.2,
using a GTF file based on Ensembl mouse NCBI37. Comparison expression levels
were made using Fragments Per Kilobase of transcript per Million (FPKM) values
using Cuffdiff from the Cufflinks package 26.
NASH diet feeding and Oil Red O staining. Twelve-week-old male mice were fed
with diet composition of 60 kcal% fat with 0.1% methionine and no added choline
(A06071302, Research Diets) for 9 weeks. Oil Red O histochemistry staining were
performed using frozen sections from mouse liver. Briefly, frozen sections were
fixed in 10% neutral formalin for 10 min, followed by treatment in 60% iso-
propanol for 5 s and then staining in Oil Red O working solution (O-0625, Sigma
Aldrich) for 15 min. This procedure was followed by washing with 60% iso-
propanol for 5 s and then water 1 min. Finally, sections were contained with
Mayer’s Hematoxylin for 3 min.
Lipidomics. A total of 50–100 mg of frozen liver are homogenized in the Omni
Bead Ruptor Elite with 2 mL homogenizer tube system (Omni, 19-628D). Samples
are homogenized in cold phosphate-buffered saline (PBS) for 3 cycles of 10 s each
at 5 m/s with a 10 s dwell time between cycles. A total of 3–6 mg of homogenized
material are applied to a modified Bligh and Dyer extraction26. Prior to biphasic
extraction, a 13 lipid class Lipidyzer Internal Standard Mix is added to each sample
(AB Sciex, 5040156). Following two successive extractions, pooled organic layers
are dried down in a Genevac EZ-2 Elite. Lipid samples are resuspended in 1:1
methanol/dichloromethane with 10 mM ammonium acetate and transferred to
robovials (Thermo 10800107) for analysis.
Samples are analyzed on the Sciex Lipidyzer Platform for targeted quantitative
measurement of 1100 lipid species across 13 lipid sub-classes. Differential Mobility
Device on Lipidyzer is tuned with SelexION tuning kit (Sciex 5040141). Instrument
settings, tuning settings, and MRM list available upon request. Data analysis
performed on Lipidyzer software. Quantitative values are normalized to milligrams
of material used.
Chromatin immunoprecipitation. ChIP experiments were performed as we pre-
viously described with exception of a few changes25. For RALY ChIP, 20 million cells
were used for each sample and four replicates were performed for each group.
Sonication was performed using a M220 Focused-ultrasonicator (Covaris) according
to the manufacturer’s protocol (10min for cells), and chromatin was immunopreci-
pitated with 4 μg antibodies against RALY (Ab170105, Abcam) overnight at 4 °C.
ChIP-Seq libraries were prepared using the Kapa LTP Library Preparation Kit (Kapa
Biosystems). ChIP-Seq was performed as described27. Bowtie2 was used for alignment
and we identified Raly enriched peaks in using by Homer findPeaks28 with FDR <
0.01. The called peaks were subsequently used for identifying the motifs enrichment
by PscanChIP29. For NFY ChIP, chromatin samples from mice livers were prepared
using truChIP Chromatin Shearing Tissue Kit (Covaris) according to manufacturer’s
recommendation. Sonication was performed using a M220 Focused-ultrasonicator
(Covaris) according to the manufacturer’s protocol for 12min, and chromatin was
immunoprecipitated with 6 µg antibodies against NFYA subunit (sc-17753×, Santa
Cruz Biotechnology) overnight at 4 °C. The ChIP samples were analyzed by real-time
PCR using primers listed in Supplementary Table 1. All values obtained were nor-
malized to the primers of negative control region.
ATAC-seq. ATAC-seq was optimized in liver after several modifications from
original Buenstero protocol19. A total of 100 mg of frozen liver were grinded to fine
powder using cellcrusher and 1 mL of ice cold nuclei isolation buffer was added
(20 mM Tris-HCl, 50 mM EDTA, 5 mM spermidine, 0.15 mM spermine, 0.1%
mercaptoethanol, 40% glycerol, pH 7.5, mM EGTA, and 60 mM KCl). After 5 min
of cooling on ice, cell suspension was filtered through Miracloth (Calbiochem)
followed by centrifugation at 1100 × g for 10 min at 4 °C. Pellet was resuspended
with 50 µL RSB buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl2, and pH 7.4)
followed by centrifugation at 500 × g for 5 min at 4 °C and resuspension in PBS. A
total of 75,000 nuclei pellet were used for transposase reaction. The rest of the
protocol followed that described by Buenstero. ATAC-Seq libraries were prepared
using the Nextera Tn5 Transposase and DNA library preparation kit (Illumina) as
described19. Libraries were single-end sequenced (50 bp) on an Illumina HiSeq
2000. Reads were mapped to the mouse genome (NCBI37/mm9) using Bowtie2
and were removed from the subsequent analysis if they were duplicated, mapped to
mitochondrial genome, or aligned to unmapped contiguous sequences. Peak calling
was performed using MACS2. The reads were converted to reads per thousand base
pairs peak per million mapped reads (RPKM) by dividing by the total number of
reads per sample. The average RPKM from four replicates was used to quantify the
accessibility across all called peaks.
Statistical analysis. A non-paired Student’s t-test was used to determine statistical
significance, defined at P < 0.05. For multiple group experiments analysis of var-
iance was used followed by multiple group analysis. Unless otherwise noted, error
bars represent standard deviations. Experiments were independently performed at
least twice. Sample size is based on statistical analysis of variance and prior
experience with similar in vivo studies.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data that support the findings of this study have been deposited in GEO with the
following accession number GSE133166. All other relevant data supporting the key
findings of this study are available within the article and its Supplementary Information
files or from the corresponding author upon reasonable request. The source data
underlying Figs. 1b, f–h, 2a–e, h, and 4c–h, and Supplementary Figs. 2a, c, 3 and 4 are
provided as a source data file. A reporting summary for this article is available as a
Supplementary Information file.
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